Felipe Duran Biography and Net Worth

CFO of iBio

Mr. Duran served as iBio’s Vice President of Financial Planning and Analysis (FP&A) from April 2021-February 2023. In that capacity, he played a strategic role in the Company’s forecasting, business planning, management reporting, and business analytics activities. From 2016 to 2021, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, which is the third largest generic pharmaceutical company in the United States. During his tenure at Lupin, Mr. Duran increased regional net sales by double digits by implementing robust commercial pricing strategies. He also spearheaded the subsidiary at a time when it became a positive EBITDA business in the region. In addition to his Latin America duties, he ran the U.S. R&D finance group, managing and providing guidance on strategy and pipeline. Prior to joining Lupin Pharmaceuticals, he held numerous strategy positions at Teva Pharmaceuticals in both its growth markets and Latin America offices. Mr. Duran also worked as a Manager, FP&A for both Bupa and Noven Pharmaceuticals. Mr. Duran holds a B.A. in Finance and an M.B.A from the University of Miami.

What is Felipe Duran's net worth?: The estimated net worth of Felipe Duran is at least $45.51 thousand as of March 19th, 2026. Duran owns 35,974 shares of iBio stock worth more than $45,507 as of September 18th. This net worth approximation does not reflect any other investments that Duran may own. Learn More about Felipe Duran's net worth.
How do I contact Felipe Duran?: The corporate mailing address for Duran and other iBio executives is 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737. iBio can also be reached via phone at (302) 355-0650 and via email at [email protected]. Learn More on Felipe Duran's contact information.
Has Felipe Duran been buying or selling shares of iBio?: Felipe Duran has not been actively trading shares of iBio during the last ninety days. Most recently, on Thursday, March 19th, Felipe Duran bought 24,835 shares of iBio stock. The stock was acquired at an average cost of $2.02 per share, with a total value of $50,166.70. Following the completion of the transaction, the chief financial officer now directly owns 35,974 shares of the company's stock, valued at $72,667.48. Learn More on Felipe Duran's trading history.
Who are iBio's active insiders?: iBio's insider roster includes David Arkowitz (Director), and Felipe Duran (CFO). Learn More on iBio's active insiders.
Are insiders buying or selling shares of iBio?: In the last twelve months, iBio insiders bought shares 2 times. They purchased a total of 37,171 shares worth more than $75,085.42. The most recent insider tranaction occured on March, 19th when CFO Felipe Duran bought 24,835 shares worth more than $50,166.70. Insiders at iBio own 1.6% of the company. Learn More about insider trades at iBio.
Information on this page was last updated on 3/19/2026.

Felipe Duran Insider Trading History at iBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/19/2026	Buy	24,835	$2.02	$50,166.70	35,974
1/10/2025	Buy	9,191	$2.72	$24,999.52	11,139

Felipe Duran Buying and Selling Activity at iBio

iBio Company Overview

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Today's Range

Now: $1.28

$1.24

$1.30

50 Day Range

MA: $1.37

$1.18

$1.51

2 Week Range

Now: $1.28

$0.77

$3.82

Volume

210,488 shs

Average Volume

1,149,390 shs

Market Capitalization

$82.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29